specializing in ophthalmic pharmacy assumed responsibility for developing the pharmacy and collaborating with other eye center personnel. Along with managing the pharmacy on a daily basis, the pharmacist was responsible for chairing the eye center's quality improvement committee. As a member of this committee, the pharmacist was expected to participate in regular accreditation reviews by JCAHO. The eye center was scheduled for its first JCAHO review during the 1995-96 fiscal year.
The pharmacist identified, among other deficiencies, the lack of a mechanism for reporting endoph-
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thalmitis associated with surgery. The quality improvement committee determined that, initially, a focus should be placed on gathering information on cataract procedures, since most surgical procedures at the center were cataract related. However, it was understood that infection associated with all other types of surgery could be monitored as part of the same initiative.
Early in 1997, the pharmacist proposed a database for reporting all cases of endophthalmitis following cataract surgery. The quality improvement committee approved the proposal, and the database was put into use in early 1997. The department of epidemiology was asked for assistance with entering data and maintaining records.
Analysis and resolution
Reporting procedures. When a case of postsurgical endophthalmitis was identified, the pharmacist compiled patient information on a reporting form. Patients were identified by the physician performing the initial surgery in order to distinguish patients receiving their initial care from our facility from patients who were referred to our facility for treatment of their endophthalmitis. This
M A N A G E M E N T C A S E S T U D Y
was done to prevent referred patients' infections from being reported as our own nosocomial infections.
Information collected included patient name, medical record number, date on which the infection presented itself, type of surgery performed, date of surgery, and location of surgery if different from our own institution. Surgery and other interventions for treating the endophthalmitis were described, along with the physician's name and whether samples were taken and sent to the laboratory for culturing. Routine interventions for endophthalmitis include sampling the vitreous fluid for culturing, removal of the infected vitreous cavity, and intravitreal injection of antibiotics prior to closing of the surgical opening.
When a report was completed, it was sent to the epidemiology department, which entered information from the report and the patient's medical record into the endophthalmitis database. The department also indicated whether laboratory testing was under way so that the results could be entered when available. When fully completed, the database record contained the following fields: (1) patient medical record, (2) patient name, age, and sex, (3) type of intraocular lens implanted during the cataract procedure, (4) adverse-event diagnosis (endophthalmitis), (5) date when samples were taken and sent to the laboratory, (6) source of samples, (7) culture results, (8) name of physician who performed the procedure, (9) type of surgery, (10) evidence of additional medical problems, (11) name of nurse of record, and (12) name of surgical technician of record.
Nosocomial endophthalmitis cases were reported for the period from January 1997 to March 2001. Cases were then compared with pharmacy dispensing records to identify the antibiotic prescribed for each case postoperatively. The first reported case of endophthalmitis occurred on April 4, 1997. Each case was reviewed by the quality improvement committee monthly to identify the problems that may have contributed and to minimize the likelihood of similar infections occurring in the future. Infection rates were reported to the faculty and the physician staff for review and comparison with rates reported by other centers around the country.
All data were entered into the endophthalmitis database by the epidemiology department staff assigned to the database. No other personnel were allowed access for entering or altering any information. This helped to ensure objective, unbiased, and secure data for analysis.
Standardization of care. The pharmacist proposed standardization of care for all cataract procedures prior to the four-year data-collection period to promote accurate, consistent evaluation of data. This proposal was accepted and put into place before January 1997. As a result, patients undergoing cataract surgery received standardized preoperative, intraoperative, and postoperative care throughout the period. Drug therapy throughout all procedures was also standardized. Preoperatively, patients received the following medications: (1) one drop of an antiinflammatory agent every five minutes for three doses, (2) one drop of a mydriatic or cycloplegic agent every five minutes for three doses, (3) one drop of preservative-free bupivicaine 0.75% solution every five minutes for three doses, and (4) one drop of ciprofloxacin 0.3% solution upon arrival in the operating room and on an on-call basis.
Patients were prepared for surgery by performing a standardized surgical scrub procedure with povidoneiodine 5% solution as a topical antiseptic. Anesthesia was achieved with either topical anesthetics or local retrobulbar injection methods. Cataract surgery was performed by phacoemulsification with intraocular lens implantation.
Postoperatively, patients were prescribed a combination of antibiotic and corticosteroid eyedrops, with or without an antiinflammatory eyedrop, depending on physician preference and patient medical history. Patients were prescribed the following postoperative drug regimens: (1) ofloxacin 0.3% solution drops or ciprofloxacin 0.3% solution drops four times daily until the surgical wound was healed, (2) diclofenac 0.1% solution drops or ketorolac 0.5% solution drops to be used four times daily until directed otherwise by the physician, and (3) prednisolone 1.0% solution drops to be used four times daily until directed otherwise by the physician. Patients received either an antibiotic and the corticosteroid only or a combination of all three drugs for use after discharge from the surgery center. Selection of the postoperative drug regimen depended on physician preference and patient medical history.
The pharmacist monitored and evaluated reported infections as they occurred. After the four-year period, the pharmacist received approval from the institutional review board to conduct detailed chart reviews of the reported cases of endophthalmitis. The pharmacist also compared information from the chart reviews with the pharmacy dispensing database to identify the medications prescribed at discharge for all the patients involved.
The epidemiology department controlled all database operations for reporting infections as they occurred. Comparisons between infection reports and the pharmacy's dispensing database, which identified which drops were dispensed to the patient at discharge, were not made until after the four-year reporting period. All data were analyzed by independent statisticians using chi-square and Fisher's exact tests and odds ratios. The a priori level of significance was 0.05.
Findings of reviews. Cataract surgery was performed on a total of 9079 patients between April 1, 1997, and March 1, 2001 . Postsurgical endophthalmitis was reported for 26 patients. Data for 5 of these patients were eliminated from the final analysis because their surgeries were complicated, which may have affected the development of endophthalmitis. Therefore, 21 patients were included in the final analysis. The rate of endophthalmitis associated with cataract surgery at our institution was thus 0.23% (2.3 cases per 1000 patients).
There were no significant differences among individual physicians in endophthalmitis rates or in cataractsurgery times.
Patient compliance with a prescribed drug regimen may potentially affect the development of postoperative infection. The cataract patients received extensive education, monitoring, and follow-up in order to maximize compliance. During the four-year period, overall compliance with postoperative medications was greater than 90% among the 9079 patients who received surgery.
The most commonly identified organism was coagulase-negative Staphylococcus species, recovered from 10 of the 21 patients, one of whom also had Propionibacterium acnes isolated. The following were recovered from the remaining 11 patients: Staphylococcus aureus was recovered from 2, Enterococcus species was recovered from 2, and other streptococci were recovered from 2. Cultures from 4 patients demonstrated no growth, and no samples were obtained for 1 patient. For cultures for which no growth was reported, one Gram stain demonstrated 3+ and another 1+ acute inflammatory cells. Patient charts and laboratory reports were reviewed to compare susceptibilities to the postoperative antibiotic used. Susceptibility to the antibiotic prescribed was found for all 21 patients.
The only variable that differed significantly among patients throughout the four-year period was the postoperative antibiotic prescribed. The pharmacy database of prescriptions dispensed at discharge was then reviewed to determine prescribing habits. A total of 4538 patients (49.98%) were prescribed ciprofloxacin, and 4541 patients (50.02%) received ofloxacin.
Seventeen (81%) of the 21 patients were prescribed ciprofloxacin as their postoperative antibiotic, and the other 4 patients (19%) were prescribed ofloxacin (p = 0.004, chisquare test and Fisher's exact test). Directions for use were the same for both agents. When the 4 patients for whom cultures yielded no bacterial growth were eliminated from the analysis, 14 (82%) of 17 patients received ciprofloxacin (p = 0.007). Of the 5 patients omitted from the primary analysis because of complicated surgeries, 4 received ciprofloxacin. Including these patients in our study would yield similar results with even greater statistical significance.
Patients who were prescribed ciprofloxacin were 4.265 times more likely to develop endophthalmitis postoperatively than patients given ofloxacin (95% confidence interval, 1.39-17.43). The rate of endophthalmitis with ofloxacin over the four-year period was only 0.089%. Having identified a variable that significantly affected the center's endophthalmitis rate, we applied qualityimprovement principles to our results and implemented changes to improve future outcomes. Specifically, the pharmacy proposed and was authorized to standardize postoperative antibiotic use to ofloxacin exclusively for all surgeries performed at the institution. No other interventions were made other than the change in antibiotic. Cataract surgeries were to continue to be monitored and endophthalmitis cases reported through the database for an additional 12 months, after which a reevaluation would be made.
Over 2500 additional cataract surgeries were performed during the following 12 months. Only one case of endophthalmitis was reported. The endophthalmitis rate was now 0.04%, or more than six times lower than the previous rate of 0.23%. The center's physicians and the quality improvement committee decided that ofloxacin would continue to be used as the only antibiotic for all surgeries performed at the institution and that the database would continue to be reviewed annually to ensure a continued low rate of endophthalmitis.
Discussion
Endophthalmitis is an uncommon but potentially devastating complication of cataract surgery. Depending on the type of infectious organism, vision may be destroyed within days. Prophylactic use of antibiotics before and after surgery may limit or avoid adverse outcomes.
1,2
The true rate of endophthalmitis following cataract surgery is uncertain, since most physicians do not accurately assess or document endophthalmitis cases within their practices. A rate of less than 1 case per 1000 surgeries has generally been accepted by physicians as the national rate; however, recent studies suggest that the rate may be as high as 4 cases per 1000 surgeries. 3, 4 JCAHO has established as one of its standards the surveillance, prevention, and control of infection. 5 To achieve this, JCAHO prescribes (1) identifying cases of infection, (2) analyzing the infections to delineate trends, causes, and possible solutions, (3) preventing future cases by developing policies, procedures, education, and other measures, and (4) monitoring and reporting the effectiveness of the interventions.
JCAHO provides processimprovement models to guide health care organizations in a step-by-step approach to meeting qualityimprovement goals. 6 Throughout our project, we used JCAHO's "FOCUS-PDCA" model. The FOCUS part consists of the following: Find a process to improve, organize a team to work on the improvement, clarify current knowledge of the process, understand the variables, and select the process for implementing improvement. Once FOCUS was complete, we moved on to PDCA: plan how to improve the process, do the planned changes, check the effect, and act to maintain any improvements achieved.
Recently, JCAHO revised this model for process improvement (Figure 1 ). The current model outlines concepts for design, data collection and analysis, performance improvement, and redesigning the original design as necessary on the basis of ongoing findings. The overall concept, however, is the same as with the FOCUS-PDCA model. Performance improvement is cyclic and ongoing, requiring continuing commitment to the overall goal of enhancing patient outcomes.
We were able to identify among all variables the single variable, antibiotic prescribed, that when changed might be expected to decrease the endophthalmitis rate and improve surgical outcomes. This finding must be viewed, however, in the context of the study's limitations. One limitation was the retrospective nature of the data analysis. In addition, our study did not have a control group. The number of patients affected by endophthalmitis is so small that achieving a sufficiently large patient base for a randomized controlled trial within a single organization would be impossible. Nevertheless, we felt it important to attempt to determine the significance of the trends we observed and to validate the data as much as possible. Statistical analysis enabled us to examine potential variables that may have confounded the results and determine as best as possible which variable stood out as potentially the greatest determinant of the infection rate observed.
The average cost of a case of endophthalmitis to our facility is $11,263. The annual cost per year before the rate was reduced was therefore $73,210. Only one case of endophthalmitis was reported during the year following our qualityimprovement efforts, avoiding nearly $62,000 in costs annually. This calculation does not even take into account possible litigation costs, which can stretch into the millions of dollars.
The general perception in ophthalmology has been that the postoperative antibiotic used is not the critical element in preventing endophthalmitis. Rather, the use of topical povidone-iodine solution during presurgical preparation has been seen as the most critical factor. 1 Our results suggest that the use and correct choice of a postoperative antibiotic may play a bigger role in endophthalmitis prevention than previously thought. Further study is needed to verify this.
Conclusion
Applying the principles of quality improvement at an eye clinic appeared to reduce the rate of endophthalmitis in cataract-surgery patients. Randomized clinical trials are needed to verify whether using ofloxacin rather than ciprofloxacin postsurgically truly reduces the frequency of this complication. 
II Need for Greater Scrutiny of Days Supply Values in DACON Calculations
To the Editor: Daily average consumption (DACON) is a technique used by pharmaceutical companies and managed care organizations to determine drug product cost per day of therapy. This method enables cost comparisons of agents with similar therapeutic indications. It may be reliable for solid dosage forms but can lead to aberrant results when applied to topical pharmaceuticals. Formulary decision makers could draw misleading conclusions about the daily cost of therapy. DACON is routinely calculated using claims data by dividing the total days supply of a product by the total units (tablets, capsules, milliliters, etc.) dispensed. To better illustrate the pitfalls of DACON calculations, we'll refer to an actual case involving a large eastern Medicaid program and a decision it was trying to reach concerning topical ophthalmic agents. The Medicaid plan in question decided to create a preferred drug list (i.e., a formulary) to better manage its costs. It looked at the aggregate data from its pharmacy benefit manager (PBM) for a 2-month period. Table 1 shows the initial DACON calculations that were prepared for presentation to the state' s Medicaid pharmacy director.
As can be noted in this table, it indicates that 4.55 milliliters of Lumigan are being used daily as are 6.5 mls of Travatan and 7.5 mls of Xanatan. We know these utilization results lie beyond common sense, leading us to presume that using the DACON calculations that one would use for solid dosage forms simply do not work in this case.
Pharmacists and pharmacy technicians tend to use routine values for the days supply field to avoid rejection of prescription claim transactions. For example, the standard days supply for topical products is 15 days; for inhalation, otic, or ocular preps, 15, 20, or 30 days. The objective in most community pharmacies is to fill the prescription as efficiently as possible, estimating the days supply using shortcuts or a rule of thumb for the days supply field. Claims processing systems used by PBMs will routinely reject a refill claim if the refill date is too soon (based on the date of the prior fill); i.e., if the refill date is not equal to or greater than a certain percentage, such as 80%, of the estimated days supply entered on the prior fill, the claim will be rejected. What is considered "efficient" pharmacy practice by the chain pharmacies also renders incorrect the DACON calculations that are derived from the days supply values.
The industry standard benefit design among PBMs is to not adjudicate a claim for a supply greater than 30 days in a community pharmacy. While some exceptions may exist in some drug benefit designs, i.e., oral contraceptives or insulin, the 30-day paradigm is still utilized. Since the average chain pharmacy deals with hundreds of different payer plans, it' s easy to see why these "rules" exist. Since PBM claim systems sometimes are programmed to not accept a days supply greater than 30, this is the maximum number entered even though the pharmacy personnel know that the prescription will often exceed that number of days.
In the case where a product is available in different volume bottles, each with a different market share, the DACON calculations become even more confusing. Table 2 shows 2 sets of calculations based on the PBM data from Table 1 where the DACONs have been recalculated using different, yet realworld, criteria. Calculation 1 shows the DACONs for the prostaglandins and prostamide agents using the total prescriptions as reported by the PBM and the days supply per bottle as reported in the literature. Calculation 2 shows the DACONs based on the days supplies that were most likely entered by the community pharmacies that are generally permitted by PBM systems. Figure 1 gives a visual representation comparing the 2 calculations in Table 2 .
A dataset with only 2 months of data may also lead to anomalies in the calculations. For example, since 60 days is less than the estimated days supply of larger size or multiple-container prescriptions, a refill cycle is not captured. This "clipping" of the data would result in falsely shortening the days supply when actual refill dates (in lieu of the entered days supply) are used to compute the length of time.
L E T T E R S
The SKU numbers used in Table 2 show the national SKU mix. These are the total annual sales in the United States and are shown as percentages of each package size of each of the 3 products. (For example, 55.2% of all Lumigan sales are for the 2.5 ml bottle.) The SKU mix was not used in the calculations in Table 1 , acting as one of the factors that led to erroneous results. We realize that Calculation 1 in Table 2 assumes that the patients waste no medication, i.e., do not miss the eye, lose a drop, etc. This is a best-case scenario. Calculation 2 shows how the DACONs can be skewed by using the days supply that most PBMs use as defaults. This represents the worst-case scenario.
In either case, the estimations of the DACONs for these 3 products are still more accurate than the calculations using empirical PBM data as shown is Table 1 . We suggest using a weighted average of the 2 calculations from 
